The U.S. Food and Drug Administration has approved the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) pivotal randomized controlled trial, which is planned to enroll 668 patients undergoing treatment for STEMI, Abiomed (Danvers, Massachusetts) announced Thursday.